Longitudinal volume changes of the pituitary gland in patients with schizotypal disorder and first-episode schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 1, 2011, Pages 177-183

  Takahashi, Tsutomu ^a,b   Zhou, Shi Yu ^c   Nakamura, Kazue ^a   Tanino, Ryoichiro ^a   Furuichi, Atsushi ^a   Kido, Mikio ^a   Kawasaki, Yasuhiro ^a,b   Noguchi, Kyo ^a   Seto, Hikaru ^a   Kurachi, Masayoshi ^a   Suzuki, Michio ^a,b  

^a UNIVERSITY OF TOYAMA   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Hypothalamic pituitary adrenal axis; Magnetic resonance imaging; Pituitary gland; Schizophrenia; Schizotypal disorder

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DELUSION; DRUG EFFICACY; FEMALE; HUMAN; HYPOPHYSIS DISEASE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN SIZE; PITUITARY GLAND ENLARGEMENT; PITUITARY GLAND VOLUME; PREDICTION; RATING SCALE; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SCORING SYSTEM; THOUGHT DISORDER; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; PITUITARY GLAND; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 78650961119     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.10.023     Document Type: Article

References (51)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington, DC. 4th ed.
2. Andreasen N.C. Scale for the Assessment of Negative Symptoms/Scale for the Assessment of Positive Symptoms [Manual] 1984, University of Iowa Press, Iowa City.
3. Andreasen N.C., Flaum M., Arndt S. The Comprehensive Assessment of Symptoms and History (CASH): an instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 1992, 49:615-623.
4. Axelson D.A., Doraiswamy P.M., Boyko O.B., Rodrigo Escalona P., McDonald W.M., Ritchie J.C., et al. In vivo assessment of pituitary volume with magnetic resonance imaging and systematic stereology: relationship to dexamethasone suppression test results in patients. Psychiatry Res 1992, 44:63-70.
5. Bschor T., Adli M., Baethge C., Eichmann U., Ising M., Uhr M., et al. Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. Neuropsychopharmacology 2002, 27:470-478.
6. Cohrs S., Röher C., Jordan W., Meier A., Huether G., Wuttke W., et al. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology (Berl) 2006, 185:11-18.
7. Dickey C.C., McCarley R.W., Niznikiewicz M.A., Voglmaier M.M., Seidman L.J., Kim S., et al. Clinical, cognitive, and social characteristics of a sample of neuroleptic-naive persons with schizotypal personality disorder. Schizophr Res 2005, 78:297-308.
8. Elster A.D. Modern imaging of the pituitary. Radiology 1993, 187:1-14.
9. Garner B., Pariante C.M., Wood S.J., Velakoulis D., Phillips L., Soulsby B., et al. Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biol Psychiatry 2005, 58:417-423.
10. Garner B., Berger G.E., Nicolo J.P., Mackinnon A., Wood S.J., Pariante C.M., et al. Pituitary volume and early treatment response in drug-naïve first-episode psychosis patients. Schizophr Res 2009, 113:65-71.
11. Goyal R.O., Sagar R., Ammini A.C., Khurana M.L., Alias A.G. Negative correlation between negative symptoms of schizophrenia and testosterone levels. Ann NY Acad Sci 2004, 1032:291-294.
12. Hirayasu Y., McCarley R.W., Salisbury D.F., Tanaka S., Kwon J.S., Frumin M., et al. Planum temporale and Heschl gyrus volume reduction in schizophrenia: a magnetic resonance imaging study of first-episode patients. Arch Gen Psychiatry 2000, 57:692-699.
13. Kasai K., Shenton M.E., Salisbury D.F., Hirayasu Y., Onitsuka T., Spencer M.H., et al. Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia. Arch Gen Psychiatry 2003, 60:766-775.
14. Kato K., Saeki N., Yamaura A. Morphological changes on MR imaging of the normal pituitary gland related to age and sex: main emphasis on pubescent females. J Clin Neurosci 2002, 9:53-56.
15. Kawasaki Y., Suzuki M., Nohara S., Hagino H., Takahashi T., Matsui M., et al. Structural brain differences in patients with schizophrenia and schizotypal disorder demonstrated by voxel-based morphometry. Eur Arch Psychiatry Clin Neurosci 2004, 254:406-414.
16. Krishnan K.R., Doraiswamy P.M., Lurie S.N., Figiel G.S., Husain M.M., Boyko O.B., et al. Pituitary size in depression. J Clin Endocrinol Metab 1991, 72:256-259.
17. Lurie S.N., Doraiswamy P.M., Husain M.M., Boyko O.B., Ellinwood E.H., Figiel G.S., et al. In vivo assessment of pituitary gland volume with magnetic resonance imaging: the effect of age. J Clin Endocrinol Metab 1990, 71:505-508.
18. MacMaster F.P., Kusumakar V. MRI study of the pituitary gland in adolescent depression. J Psychiatr Res 2004, 38:231-236.
19. MacMaster F.P., Keshavan M., Mirza Y., Carrey N., Upadhyaya A.R., El-Sheikh R., et al. Development and sexual dimorphism of the pituitary gland. Life Sci 2007, 80:940-944.
20. MacMaster F.P., El-Sheikh R., Upadhyaya A.R., Nutche J., Rosenberg D.R., Keshavan M. Effect of antipsychotics on pituitary gland volume in treatment-naïve first-episode schizophrenia: a pilot study. Schizophr Res 2007, 92:207-210.
21. Miki Y., Kataoka M.L., Shibata T., Haque T.L., Kanagaki M., Shimono T., et al. The pituitary gland: changes on MR images during the 1st year after delivery. Radiology 2005, 235:999-1004.
22. Mitropoulou V., Goodman M., Sevy S., Elman I., New A.S., Iskander E.G., et al. Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizotypal personality disorder. Schizophr Res 2004, 70:27-31.
23. Mittal V.A., Dhruv S., Tessner K.D., Walder D.J., Walker E.F. The relations among putative biorisk markers in schizotypal adolescents: minor physical anomalies, movement abnormalities, and salivary cortisol. Biol Psychiatry 2007, 61:1179-1186.
24. Mondelli V., Dazzan P., Gabilondo A., Tournikioti K., Walshe M., Marshall N., et al. Pituitary volume in unaffected relatives of patients with schizophrenia and bipolar disorder. Psychoneuroendocrinology 2008, 33:1004-1012.
25. Nicolo J.P., Berger G.E., Garner B.A., Velakoulis D., Markulev C., Kerr M., et al. The effect of atypical antipsychotics on pituitary gland volume in patients with first-episode psychosis: a longitudinal MRI study. Schizophr Res 2010, 116:49-54.
26. Nordentoft M., Thorup A., Petersen L., Ohlenschlaeger J., Melau M., Christensen T.Ø., et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res 2006, 83:29-40.
27. Pariante C.M., Vassilopoulou K., Velakoulis D., Phillips L., Soulsby B., Wood S.J., et al. Pituitary volume in psychosis. Br J Psychiatry 2004, 185:5-10.
28. Pariante C.M., Dazzan P., Danese A., Morgan K.D., Brudaglio F., Morgan C., et al. Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology 2005, 30:1923-1931.
29. Peiffer A., Veilleux S., Barden N. Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology 1991, 16:505-515.
30. Phillips L.J., McGorry P.D., Garner B., Thompson K.N., Pantelis C., Wood S.J., et al. Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders. Aust N Z J Psychiatry 2006, 40:725-741.
31. Sassi R.B., Nicoletti M., Brambilla P., Harenski K., Mallinger A.G., Frank E., et al. Decreased pituitary volume in patients with bipolar disorder. Biol Psychiatry 2001, 50:271-280.
32. Scheepers F.E., Gespen de Wied C.C., Kahn R.S. The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia. J Clin Psychopharmacol 2001, 21:575-582.
33. Schooler N., Rabinowitz J., Davidson M., Emsley R., Harvey P.D., Kopala L., et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005, 162:947-953.
34. Siever L.J., Davis K.L. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am J Psychiatry 2004, 161:398-413.
35. Suzuki M., Zhou S.Y., Takahashi T., Hagino H., Kawasaki Y., Niu L., et al. Differential contributions of prefrontal and temporolimbic pathology to mechanisms of psychosis. Brain 2005, 128:2109-2122.
36. Takahashi T., Kawasaki Y., Kurokawa K., Hagino H., Nohara S., Yamashita I., et al. Lack of normal structural asymmetry of the anterior cingulate gyrus in female patients with schizophrenia: a volumetric magnetic resonance imaging study. Schizophr Res 2002, 55:69-81.
37. Takahashi T., Suzuki M., Zhou S.Y., Tanino R., Hagino H., Kawasaki Y., et al. Morphologic alterations of the parcellated superior temporal gyrus in schizophrenia spectrum. Schizophr Res 2006, 83:131-143.
38. Takahashi T., Suzuki M., Velakoulis D., Lorenzetti V., Soulsby B., Zhou S.Y., et al. Increased pituitary volume in schizophrenia spectrum disorders. Schizophr Res 2009, 108:114-121.
39. Takano K., Utsunomiya H., Ono H., Ohfu M., Okazaki M. Normal development of the pituitary gland: assessment with three-dimensional MR volumetry. AJNR Am J Neuroradiol 1999, 20:312-315.
40. Toru M. Psychotropic manual 2001, Igaku-Shoin, Tokyo. Second ed.
41. Tournikioti K., Tansella M., Perlini C., Rambaldelli G., Cerini R., Versace A., et al. Normal pituitary volumes in chronic schizophrenia. Psychiatry Res 2007, 154:41-48.
42. Upadhyaya A.R., El-Sheikh R., MacMaster F.P., Diwadkar V.A., Keshavan M.S. Pituitary volume in neuroleptic-naïve schizophrenia: a structural MRI study. Schizophr Res 2007, 90:266-273.
43. Walder D.J., Walker E.F., Lewine R.J. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol Psychiatry 2000, 48:1121-1132.
44. Walker E.F., Walder D.J., Reynolds F. Developmental changes in cortisol secretion in normal and at-risk youth. Dev Psychopathol 2001, 13:721-732.
45. Walker E., Mittal V., Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu Rev Clin Psychol 2008, 4:189-216.
46. Walker E.F., Brennan P.A., Esterberg M., Brasfield J., Pearce B., Compton M.T. Longitudinal changes in cortisol secretion and conversion to psychosis in at-risk youth. J Abnorm Psychol 2010, 119:401-408.
47. Watson S., Gallagher P., Ritchie J.C., Ferrier I.N., Young A.H. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 2004, 184:496-502.
48. World Health Organization The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research 1993, World Health Organization, Geneva.
49. Yap H.L., Mahendran R., Lim D., Liow P.H., Lee A., Phang S., et al. Risperidone in the treatment of first episode psychosis. Singapore Med J 2001, 42:170-173.
50. Zhou S.Y., Suzuki M., Hagino H., Takahashi T., Kawasaki Y., Nohara S., et al. Decreased volume and increased asymmetry of the anterior limb of the internal capsule in patients with schizophrenia. Biol Psychiatry 2003, 54:427-436.
51. Zobel A.W., Nickel T., Sonntag A., Uhr M., Holsboer F., Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. A prospective study. J Psychiatr Res 2001, 35:83-94.